Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
Total Valuation
Edwards Lifesciences has a market cap or net worth of $40.94B. The enterprise value is $40.50B.
Market Cap$40.94B
Enterprise Value$40.50B
Share Statistics
Edwards Lifesciences has 585.76M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding585.76M
Owened by Insiders0.93%
Owened by Instutions19.18%
Financial Efficiency
Edwards Lifesciences’s return on equity (ROE) is 0.42 and return on invested capital (ROIC) is 10.72%.
Return on Equity (ROE)41.75%
Return on Assets (ROA)31.98%
Return on Invested Capital (ROIC)10.72%
Return on Capital Employed (ROCE)11.94%
Revenue Per Employee$362,297.468
Profits Per Employee$264,215.19
Employee Count15,800
Asset Turnover0.42
Inventory Turnover1.03
Valuation Ratios
The current PE Ratio of Edwards Lifesciences is 10.60. Edwards Lifesciences’s PEG ratio is 0.05.
PE Ratio10.60
PS Ratio8.13
PB Ratio4.43
Price to Fair Value4.43
Price to FCF152.63
Price to Operating Cash Flow81.59
PEG Ratio0.05
Income Statement
In the last 12 months, Edwards Lifesciences had revenue of $5.72B and earned $4.17B in profits. Earnings per share was $6.98.
Revenue$5.72B
Gross Profit$4.49B
Operating Income$1.51B
Pretax Income$1.59B
Net Income$4.17B
EBITDA1.81B
Earnings Per Share (EPS)6.98
Cash Flow
In the last 12 months, operating cash flow was $542.30M and capital expenditures -$252.40M, giving a free cash flow of $289.90M billion.
Operating Cash Flow$542.30M
Free Cash Flow$289.90M
Free Cash Flow per Share$0.49
Dividends & Yields
Edwards Lifesciences pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield0.66%
Earnings Yield9.43%
Stock Price Statistics
Beta0.98
52-Week Price Change-24.39%
50-Day Moving Average71.44
200-Day Moving Average71.76
Relative Strength Index (RSI)54.05
Average Volume (3m)4.98M
Important Dates
Edwards Lifesciences upcoming earnings date is Apr 23, 2025, After Close.
Last Earnings DateFeb 11, 2025
Next Earnings DateApr 23, 2025
Ex-Dividend Date―
Financial Position
Edwards Lifesciences as a current ratio of 4.18, with Debt / Equity ratio of 0.07
Current Ratio4.18
Quick Ratio3.45
Debt to Market Cap0.01
Net Debt to EBITDA-1.36
Interest Coverage Ratio69.63
Taxes
In the past 12 months, Edwards Lifesciences has paid $164.40M in taxes.
Income Tax$164.40M
Effective Tax Rate9.82%
Enterprise Valuation
Edwards Lifesciences EV to EBITDA ratio is 24.32, with an EV/FCF ratio of 144.54.
EV to Sales7.70
EV to EBITDA24.32
EV to Free Cash Flow144.54
EV to Operating Cash Flow77.27
Balance Sheet
Edwards Lifesciences has $3.98B in cash and marketable securities with $700.00M in debt, giving a net cash position of -$3.28B billion.
Cash & Marketable Securities$3.98B
Total Debt$700.00M
Net Cash-$3.28B
Net Cash Per Share-$5.59
Tangible Book Value Per Share$11.89
Margins
Gross margin is 79.46%, with operating margin of 25.35%, and net profit margin of 76.75%.
Gross Margin79.46%
Operating Margin25.35%
Pretax Margin28.46%
Net Profit Margin76.75%
EBITDA Margin31.68%
EBIT Margin28.82%
Analyst Forecast
The average price target for Edwards Lifesciences is $77.36, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$77.36
Price Target Upside13.33%
Analyst ConsensusModerate Buy
Analyst Count19
Revenue Growth Forecast-4.67%
EPS Growth Forecast6.23%